Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IXHL |
---|---|---|
09:32 ET | 314 | 2.06 |
09:44 ET | 150 | 2.09 |
10:31 ET | 420 | 2.0702 |
10:38 ET | 150 | 2.075 |
10:45 ET | 100 | 2.05 |
11:21 ET | 1900 | 2.04 |
11:52 ET | 211 | 2.04 |
12:24 ET | 100 | 2.05 |
12:26 ET | 200 | 2.045 |
12:28 ET | 100 | 2.055 |
12:37 ET | 200 | 2.05 |
01:47 ET | 300 | 2.04 |
02:00 ET | 200 | 2.07 |
02:23 ET | 100 | 2.03 |
02:54 ET | 501 | 2.0345 |
03:03 ET | 600 | 2.0101 |
03:24 ET | 100 | 2.0199 |
03:32 ET | 3600 | 2.0101 |
03:35 ET | 1113 | 2.01 |
03:37 ET | 1800 | 2 |
03:39 ET | 414 | 1.96 |
03:55 ET | 2600 | 1.96 |
04:00 ET | 689 | 1.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Incannex Healthcare Inc | 34.8M | -1.4x | --- |
BioQuest Corp | 10.9M | -19.6x | --- |
TherapeuticsMD Inc | 15.3M | -3.8x | --- |
Talphera Inc | 11.9M | -1.0x | --- |
SYBLEU Inc | 5.5M | -1.9x | --- |
Sentient Brands Holdings Inc | 5.1M | -4.1x | --- |
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.8M |
---|---|
Revenue (TTM) | $86.0K |
Shares Outstanding | 17.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.40 |
Book Value | $0.71 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 404.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -36,506.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.